# A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis

> **NCT01395004** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 17 (actual)

## Conditions studied

- Langerhans Cell Histiocytosis

## Interventions

- **DRUG:** GSK2110183

## Key facts

- **NCT ID:** NCT01395004
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01395004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01395004, "A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01395004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*